SCHEMBL6501037

SCHEMBL6501037

CC(=O)Nc1cccc(CCC(=O)c2ccc(NC(=O)c3ccc(C)cc3-c3ccc(C)cc3)cc2)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 1/20 0.41
ALDH1A1 P00352 4/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
RECQL P46063 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
HTT P42858 1/20 0.39
HPGD P15428 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ADORA3 P0DMS8 2/20 0.39
SORT1 Q99523 1/20 0.39
AGTR1 P30556 1/20 0.38
AGTR2 P50052 1/20 0.38
KDM4E B2RXH2 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HDAC7 Q8WUI4 1/20 0.38
PDE10A Q9Y233 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498569 0.86 ALOX15 (0.44) GCGRKMT2AMAPTSMN1; SMN2SORT1
SCHEMBL6490419 0.84 L3MBTL1 (0.46) GCGRKMT2AMAPTMEN1RECQL
SCHEMBL6493468 0.84 GCGR (0.39) GCGRKMT2AMAPTMEN1SMN1; SMN2
SCHEMBL6490949 0.81 GCGR (0.44) GCGRKMT2AMAPTMEN1SMN1; SMN2
SCHEMBL6793643 0.81 MTTP (0.51) ADORA3KDM4E
SCHEMBL6488352 0.80 SMO (0.45) GCGRADORA3SORT1ALOX15
SCHEMBL6488561 0.79 SMO (0.43) GCGRRECQLADORA3SORT1ALOX15
SCHEMBL6492353 0.79 TUBB4A (0.47) GCGRALDH1A1KMT2AMAPTMEN1
SCHEMBL6492359 0.79 TUBB4A (0.47) GCGRALDH1A1KMT2AMAPTMEN1
SCHEMBL7080710 0.78 SORT1 (0.43) KMT2AMAPTMEN1ADORA3SORT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 GCGR 1784/4885ALDH1A1 1603/4885KMT2A 573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.